Skip to main content
Clinical Trials/ChiCTR1800015657
ChiCTR1800015657Active, not recruitingNot Applicable

LncRNA GAS5 调控糖尿病合并子宫内膜癌进展的分子机制

自筹0 sites60 target enrollmentStarted: April 18, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
60
Primary Endpoint
长链非编码 RNA 生长阻滞特异性转录物 5

Study Overview

Brief Summary

揭示 LncRNA GAS5 对糖尿病合并子宫内膜癌的保护作用。

Study Design

Study Type
病因学/相关因素研究
Primary Purpose
队列研究

Eligibility Criteria

Ages
31 to 65 (—)
Sex
Female

Inclusion Criteria

  • 收集糖尿病合并子宫内膜癌患者和单纯子宫内膜癌患者癌组织和癌旁组织标本

Exclusion Criteria

  • 内膜癌同时合并其他恶性肿瘤的患者

Arms & Interventions

子宫内膜癌合并糖尿病组

Nil

单纯子宫内膜癌组

Nil

Outcomes

Primary Outcomes

长链非编码 RNA 生长阻滞特异性转录物 5

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
自筹

Similar Trials